Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems.
Document Type
Article
Publication Date
7-30-2024
Publication Title
Thrombosis and haemostasis
Abstract
BACKGROUND: While direct oral anticoagulants (DOACs) may be viewed as simpler to manage then warfarin, they present their own unique management challenges resulting in frequent off-label dosing. It is unknown to what extent off-label dosing occurs when a patient is started on a DOAC versus later in their treatment.
OBJECTIVES: We aimed to better characterize when off-label DOAC dosing is occurring and to evaluate the effectiveness of prescribing oversight using a registry-based intervention.
METHODS: We evaluated data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI
RESULTS: Among a sample of 789 to 1,022 annual AF patients and 381 to 484 annual VTE patients prescribed a DOAC in the MAQI
CONCLUSION: This study demonstrates the benefit of DOAC prescribing oversight using a registry-based intervention to monitor for off-label dosing for the entirety of the time period a patient is prescribed DOAC, particularly for patients with AF, as off-label prescribing occurs frequently during the follow-up period.
Volume
Online ahead of print
Recommended Citation
Herron GC, DeCamillo D, Kong X, Haymart B, Kaatz S, Ellsworth S et al. [ Ali MA] Timing of Off-label dosing of direct oral anticoagulants in three large health systems. Thromb Haemost. 2024 Jul 30. doi: 10.1055/a-2365-8681. Epub ahead of print. PMID: 39009007.
DOI
10.1055/a-2365-8681.
ISSN
2567-689X
PubMed ID
39009007